Rhinology Learning Hub

Welcome to the CRSwNP learning hub focused on key scientific education on chronic rhinosinusitis with nasal polyps, featuring ADVENT resources.

CRSwNP is a chronic type 2 inflammatory disease characterized by inflammation and polyp formation that obstructs the sinus and nasal passages. It presents as nasal obstruction, rhinorrhea (nasal discharge), facial pain/pressure, and reduced or complete loss of smell. The persistent symptoms can lead to breathing difficulties, sleep disturbances including snoring, chronic fatigue, and significant reduction in quality of life.

Access the resources below to gain better understanding on a variety of topics related to CRSwNP.

CRSwNP Events of Interest

CRSwNP Events of Interest highlight congresses and latest educational opportunities relating to understanding the science of CRSwNP.

5April2024

Congress

ADVENT at IRS-ISIAN | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

Join Profs. Shigeharu Fujieda, Peter Hellings, and Eugenio De Corso for an educational symposium on the evolving understanding of disease control and clinical remission in CRSwNP.

Related events

5April2024

Congress

ADVENT at IRS-ISIAN | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

5April2024

Congress

ADVENT at IRS-ISIAN | The Importance of Understanding Smell Loss and Congestion in CRSwNP

Test your knowledge

Check your understanding of the latest clinical insights and disease management.

MAT-GLB-2504169 - 1.0 - 10/2025

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BulgariaChange country/region